Serotonin (5-HT) type 6 antagonists have been regarded as cognition-enhancing principles associated with schizophrenia and Alzheimer’s disease. It has been proposed that these favorable effects are mediated through a blockade of excitatory tonic action of 5-HT6 receptors located at GABAergic neurons in the hippocampus and cortex. This blockade is leading to an indirect enhancement of cholinergic and glutamatergic neurotransmission. To evaluate the cognitive effects of SB 742,457, the novel object recognition test (NOR) was performed following scopolamineadministration. As a positive control, galantamine, a competitive and reversible cholinesterase inhibitor, was used. We report that compound SB 742,457 reversed scopolamine-induced memory impairment in a dose-dependent manner. The effect of higher dose of 1 mg/kg was as strong as an effect of a positive control, galantamine. Present data confirm that antagonists of 5-HT6 receptors exhibit pro-cognitive effects purportedly useful in the treatment of cognitive deficits associated with Alzheimer’s disease and schizophrenia. Supported by statutory funds from the Institute of Pharmacology, Polish Academy of Sciences (Cracow, Poland)
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.